GCC targeted CAR-T cell therapy - InnobationBio/Thomas Jefferson University
Alternative Names: GCC targeted CAR-T cell therapeutics; GCC targeted CAR-T cell therapeutics Liminatus Pharma LLC/Iris Acquisition CorpLatest Information Update: 13 Dec 2022
At a glance
- Originator InnobationBio; Thomas Jefferson University
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
Most Recent Events
- 05 Dec 2022 Liminatus Pharma to develop GCC targeted CAR-T cell therapeutics for colorectal, pancreatic, gastric and esophageal cancer
- 05 Dec 2022 Preclinical in Colorectal cancer in USA (Parenteral) (Liminatus pipeline, December 2022)
- 05 Dec 2022 Preclinical in Gastric cancer in USA (Parenteral) (Liminatus pipeline, December 2022)